- PhRMA report lists 271 vaccines in development
- Walgreens partners with United Nations Foundation's Shot@Life campaign
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
- Study: Antivirals like Tamiflu, Relenza reduce deaths among children critically ill with the flu
SILVER SPRING, Md. — A new formulation of a common drug for flu will be available in lower concentrations to reduce the possibility of medication errors, the Food and Drug Administration said Wednesday.
The FDA said the change applies to the oral suspension form of Genentech’s Tamiflu (oseltamivir). The formulation is a powder that the pharmacist mixes with water to make it easier to take for patients who have difficulty swallowing capsules.
The change was made because the higher-concentration version becomes frothy when mixed, making it more difficult to measure the correct dose.